Clinical Trials Logo

Adverse Effect clinical trials

View clinical trials related to Adverse Effect.

Filter by:

NCT ID: NCT05932576 Recruiting - Adverse Effect Clinical Trials

A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women

Start date: December 1, 2022
Phase:
Study type: Observational

Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, research has confirmed that carcinogenic HPV type continuous infection leads to a higher incidence of condyloma acuminatum and cervical cancer, while increasing the oropharyngeal cancer, vaginal cancer and other related cancer risk. HPV vaccines have been widely introduced worldwide to prevent cancers of the lower genital tract such as cervical, anal and vulvar cancers. For different types of HPV vaccine, divided into domestic bivalent, imported bivalent (GlaxoSmithKline), quadrivalent (Merck) and nine-valent (Merck) HPV vaccine, four vaccines all prevent HPV 16/18 high-risk type infection disease, and the four and nine-valent HPV vaccine prevention genotypes are different, and different price number of protection rates, vaccination objects and immunization procedures are slightly different. At the same time, studies have shown that women after HPV vaccine, arm redness, swelling, heat and pain have a high incidence of adverse reactions, often accompanied by menstrual disorders, sleep problems, emotional irritability, fever, dizziness, headache and other adverse reactions risk, so we plan to design a multicenter cohort study to evaluate the effectiveness of HPV vaccine with different prices. At the same time, the adverse reaction symptoms of HPV vaccine in the female population of appropriate age were monitored.

NCT ID: NCT05932563 Recruiting - Epidemiology Clinical Trials

Study on the Epidemiological Characteristics of Female HPV Vaccination in China

Start date: January 1, 2023
Phase:
Study type: Observational

Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, studies have confirmed that carcinogenic HPV type continuous infection leads to higher incidence of condyloma acuminatum and cervical cancer, while increasing the risk of oropharyngeal cancer, vaginal cancer and other related cancers. Human papillomavirus vaccines have been widely used worldwide to prevent cancers of the lower reproductive tract, such as cervical, anal and vulvar cancers. According to the type, it is divided into domestic two-valent (Vantage), imported two-valent (GlaxoSmithKline), four-valent (Merck) and nine-valent (Merck)HPV vaccines. All four vaccines prevent high-risk HPV 16/18 infection, and there are differences between the quadrivalent and nine-valent HPV vaccine prevention genotypes. The protection rate, immunizing target and immunizing procedure of different valence number are slightly different. Studies have shown that after women receive HPV vaccine, the incidence of arm redness, swelling, fever, pain and other adverse reactions is high, often accompanied by menstrual disorders, sleep problems, emotional irritability, fever, dizziness, headache and other adverse reactions. However, the causal relationship between HPV vaccination and symptoms after vaccination at different prices is controversial, and there is little research in this area. Therefore, we intend to design a multicenter, bidirectional cohort study to investigate the relationship between HPV vaccination with different valence numbers and adverse reactions after vaccination in Chinese women, and to further explore the unknown potential factors affecting the protective effect of HPV vaccine.

NCT ID: NCT05774574 Recruiting - Appetitive Behavior Clinical Trials

Physiological and Appetitive Effects of CBD Supplementation

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

CBD may affect metabolic control and energy intake. However, there is currently little data regarding these specific outcomes in humans. Therefore, this study will investigate whether four weeks of supplementation with 60 mg/day CBD affects energy intake at a single meal, and or fasting blood-based markers of appetite regulation and metabolic health. Healthy, adult volunteers will be assigned to placebo or CBD supplementation, in a randomized controlled trial, comparing changes in outcomes across the supplementation period between groups.

NCT ID: NCT05743985 Active, not recruiting - Clinical trials for Inflammatory Response

Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over. The main questions it aims to answer are: - What effect, if any, does daily oral consumption of 50mg of full spectrum CBG have on the mental, physical, and emotional wellbeing of healthy individuals, as measured by self-report Medical Symptom Questionnaire and 36-Item Short Form Health Survey scores? - Is CBG effective at reducing inflammation in the body, as measured by HSCRP, ESR, and PSA inflammatory markers? - Do age, gender, weight, or state of body inflammation have an effect on the perceived efficacy of CBG? - What adverse effects, if any, are associated with CBG use? Over the course of the 12-week study, participants will: - Take baseline MSQ and SF-36 surveys, as well as a clinical visit with blood draws for HSCRP, ESR, and PSA testing - Consume one (1) 50mg capsule of full spectrum CBG daily by mouth with food for 8 weeks, followed by a 4-week washout period - Complete biweekly SF-36 surveys as well as MSQ surveys every 4 weeks - Attend a clinical visit every 4 weeks for clinical observation and blood draws for HSCRP, ESR, and PSA (male subjects)

NCT ID: NCT05712018 Completed - Adverse Effect Clinical Trials

Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine

Start date: October 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of different 6% hydroxyethyl starch (130/0.4) coload volumes on the 90% effective dose of norepinephrine infusion prophylaxis for hypotension during spinal anesthesia for cesarean section.

NCT ID: NCT05690334 Completed - Adverse Effect Clinical Trials

Different Crystalloid Coload Volumes on the 90% ED of Norepinephrine

Start date: March 21, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of different crystalloid coload volumes on the 90% effective dose of prophylactic norepinephrine infusions for preventing postspinal anesthesia hypotension during cesarean section.

NCT ID: NCT05475990 Completed - Adverse Effect Clinical Trials

Comparison of Hydroxyethyl Starch and Crystalloid Coload Combined With Norepinephrine Infusion for Hypotension

Start date: January 11, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the ED50 and ED90 for an effective 6% Hydroxyethyl starch (130/0.4) or crystalloid coload combined with prophylactic norepinephrine infusion dose for postspinal anesthesia hypotension in patients undergoing cesarean section.

NCT ID: NCT05475886 Recruiting - Adverse Effect Clinical Trials

6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia Hypotension

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the ED50 and ED90 for an effective 6% Hydroxyethyl starch (130/0.4) coload infusion dose for postspinal anesthesia hypotension in patients undergoing cesarean section.

NCT ID: NCT05475873 Completed - Adverse Effect Clinical Trials

Ondansetron for Postspinal Anesthesia Hypotension

Start date: June 18, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effectiveness of ondansetron for postspinal anesthesia hypotension in patients undergoing cesarean section.

NCT ID: NCT05310331 Recruiting - Chemotherapy Clinical Trials

Donafenib for Recurrent Cervical Cancer

Start date: March 27, 2022
Phase: Phase 2
Study type: Interventional

This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.